<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210312050687N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-05-14</date_registration>
      <primary_sponsor>Sabzevar University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation the  efficacy of  the probiotic  (Ramnuflor and sabular) on acute diarrhea in six months to five –year- old children referred to Heshmatieh Hospital.</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation the  efficacy of  the probiotic  (Ramnuflor and sabular) on acute diarrhea in six months to five –year- old children referred to Heshmatieh Hospital.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>180</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54996</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: With the easy sampling method, the qualified patients referred to Heshmatieh Hospital are randomly divided into three groups (2 intervention and control) after selecting the sample.  In this study, individuals were assigned to 3 groups using permutation block method.  In this method, A represents the individual receiving the first intervention, B represents the individual receiving the second intervention, and C represents the individual in the control group.  After entering the study, they will enter one of the three study groups using the six-block random method.  A set of different modes, BBCAAC BCAACB, CCAABB خواهد will be prepared by a statistician.  Using the letters A, B and C will be considered as a symbol of one of the three intervention groups.  Each of the six codes is enclosed in a sealed envelope that cannot be read from the envelope.  At the patients' visit, one of the envelopes is randomly selected and the patients are assigned to one of the study groups in the order of the letters mentioned in it.  Therefore, by selecting the numbers from the table, the method of assigning a total of 180 people to the three groups will be determined, Blinding description: Using permutation block sampling method.  Two-way blind
 The researcher (person implementing the project) and the people participating in the project are unaware of the type of treatment.</study_design>
      <phase>3</phase>
      <hc_freetext>Acute diarrhea.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Group one.  Group of children 6 months to 2 years receiving probiotic rhamnofluor.  45 people.  This group receives standard ORS and Zinc fluid therapy along with 5 mm drops of Ramenofluor with a daily dose of 10 drops for 7 days.  Raminoflor probiotic drops are from Farabiotic Company. Intervention 2: Intervention group:Group 2. Children 2 to 5 years old receiving subular probiotics.  45 people.  This group, in addition to the standard fluid therapy, ORS and Zinc, receive one subular sachet daily for 7 days.  Sapolar sac is from a parabiotic company that dissolves in liquid or solid food. Intervention 3: Control group:The group receiving routine diarrhea treatment included 45 children aged 6 months to two years and 45 children aged 2 to 5 years.  This group receives standard ORS and Zinc fluid therapy.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehdi jalili akbarian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Asad abadi St,Heshmatieh Hospital sabzevar</address>
        <city>Sabzevar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9333156683</zip>
        <telephone>+98 51 4401 1600</telephone>
        <email>jalilim56@yahoo.com</email>
        <affiliation>Heshmatieh Hospital sabzevar</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehdi jalili akbarian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Asad abadi St, Heshmatieh Hospital sabzevar</address>
        <city>Sabzevar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9333156683</zip>
        <telephone>+98 51 4401 1600</telephone>
        <email>jalilim56@yahoo.com</email>
        <affiliation>Sabzevar University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Clinical and laboratory symptoms based on chronic diarrhea.
Diarrhea lasted more than 7 days.
Be over 5 years old or under 6 months old
The patient has a known case of immunodeficiency or cancer or a known underlying disease.
Have an FTT or have a known chronic illness.
Weight less than 3% percentile
The patient has been taking probiotics for the past week
Diarrhea accompanied by involvement or infection of other examined organs.
Severe electrolyte disturbances such as hypernatremia, sodium betasherazine 145 and hypocalcemia, potassium less than 3.5
Dehydration percentage more than 10%</inclusion_criteria>
      <agemin>6 months</agemin>
      <agemax>5 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Group one.  Group of children 6 months to 2 years receiving probiotic rhamnofluor.  45 people.  This group receives standard ORS and Zinc fluid therapy along with 5 mm drops of Ramenofluor with a daily dose of 10 drops for 7 days.  Raminoflor probiotic drops are from Farabiotic Company.</i_keyword>
      <i_keyword>Intervention group:Group 2. Children 2 to 5 years old receiving subular probiotics.  45 people.  This group, in addition to the standard fluid therapy, ORS and Zinc, receive one subular sachet daily for 7 days.  Sapolar sac is from a parabiotic company that dissolves in liquid or solid food.</i_keyword>
      <i_keyword>Control group:The group receiving routine diarrhea treatment included 45 children aged 6 months to two years and 45 children aged 2 to 5 years.  This group receives standard ORS and Zinc fluid therapy.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Number of times diarrhea per day. Timepoint: For 7 days in a row. Method of measurement: interview.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Sabzevar University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-03-10</approval_date>
        <contact_name>Ethics committee Sabzevar University of Medical Sciences</contact_name>
        <contact_address>Asad abadi St.olom pezeshki sabzevar Sabzevar Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
